Nevisense for Keratinocyte Cancers

About Scibase

SciBase's mission is to pioneer prediction and prevention in skin health by empowering clinicians with advanced diagnostic tools. Its key achievement is the development and commercialization of the Nevisense platform, which has gained regulatory approval for melanoma and keratinocyte cancer detection based on robust clinical evidence. The company's strategy focuses on expanding the platform's applications, scaling commercial operations in key markets, and leveraging its unique EIS+AI technology to become a standard of care in dermatological diagnostics.

Therapeutic Areas